AbbVie
Co-markets linaclotide (Linzess) in the US with Ironwood for IBS-C and chronic constipation.
Share price
$279
Up 20% over 12 monthsWhat analysts expect
Buy
Buy80%
Hold20%
Sell0%
Price target for the next 12 months
$277Down 1.9% compared with the current price
Price now $283Average targetLowest $225 to highest $320
30 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $64B
- Yearly profit
- $6.3B
- Company value
- $493B
Revenue and profit for the last twelve months reported.
Peptides in this book
- LinaclotidePrescription
Recent news
Risk in the news: TheFly reported that AbbVie guided third-quarter and full-year 2026 earnings per share below consensus.
Prices are delayed and figures rounded. Not investment advice.